886 related articles for article (PubMed ID: 30249169)
1. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
2. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
3. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin V
Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
7. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
8. Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Brunnemer E; Wälscher J; Tenenbaum S; Hausmanns J; Schulze K; Seiter M; Heussel CP; Warth A; Herth FJF; Kreuter M
Respiration; 2018; 95(5):301-309. PubMed ID: 29490307
[TBL] [Abstract][Full Text] [Related]
9. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
10. Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE.
Kolonics-Farkas AM; Šterclová M; Mogulkoc N; Kus J; Hájková M; Müller V; Jovanovic D; Tekavec-Trkanjec J; Littnerová S; Hejduk K; Vašáková M
Drug Saf; 2020 Oct; 43(10):971-980. PubMed ID: 32734423
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events.
Bendstrup E; Wuyts W; Alfaro T; Chaudhuri N; Cornelissen R; Kreuter M; Melgaard Nielsen K; Münster AB; Myllärniemi M; Ravaglia C; Vanuytsel T; Wijsenbeek M
Respiration; 2019; 97(2):173-184. PubMed ID: 30544129
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
14. A Narrative Review of Real-World Data on the Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis.
Podolanczuk AJ; Cottin V
Adv Ther; 2023 May; 40(5):2038-2050. PubMed ID: 36928494
[TBL] [Abstract][Full Text] [Related]
15. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
[TBL] [Abstract][Full Text] [Related]
16. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Effects and Adverse Events of Nintedanib Therapy in Idiopathic Pulmonary Fibrosis Patients with Functionally Advanced Disease.
Barczi E; Starobinski L; Kolonics-Farkas A; Eszes N; Bohacs A; Vasakova M; Hejduk K; Müller V
Adv Ther; 2019 May; 36(5):1221-1232. PubMed ID: 30877478
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib for Idiopathic Pulmonary Fibrosis.
Tepede A; Yogaratnam D
J Pharm Pract; 2019 Apr; 32(2):199-206. PubMed ID: 29017422
[TBL] [Abstract][Full Text] [Related]
19. Is nintedanib effective for idiopathic pulmonary fibrosis?
Jeldres A; Labarca G
Medwave; 2017 Apr; 17(Suppl2):e6918. PubMed ID: 28430774
[TBL] [Abstract][Full Text] [Related]
20. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]